It is probable that this long persisting IGF-1 reduction will contribute to late effects, such as impaired growth, sarcopenia, endocrine disorders, metabolic syndrome and frailty seen in long-term survivors, and should be addressed in follow-up studies. This evidence concerns the gene IGF1 and sarcopenia.